In vitro toxicology testing is used to examine the toxic properties of compounds and mixtures on cultured bacteria or mammalian cells. Absorption, distribution, metabolism, and excretion (ADME), and toxicological profiling plays a major role in drug development. It focuses on obtaining an early estimate of human pharmacokinetic and metabolic profiles.

The global in vitro toxicity testing market is estimated to account for US$ 14,940.2 Mn in terms of value by the end of 2027.

Browse Summary of the Research Report-https://www.coherentmarketinsights.com/market-insight/in-vitro-toxicity-testing-market-3855

Opposition to animal testing is expected to propel growth of the global in vitro toxicity testing market over the forecast period. Concerns over animal experiments have been raised in the field of toxicity testing, owing to issues such as difference between various test animals and the resultant effect of toxicants on the animals. Various animal welfare associations and organizations have also increased their efforts towards elimination of toxicity testing on animals. Such scenario has led to increasing adoption of in vitro toxicity testing.

Moreover, various advantages of in vitro toxicity testing are also expected to aid in growth of the market. In vitro toxicity testing eliminates the use of animals from the testing procedures. It also covers a wide range of toxicity pathways and thus helps in convenient testing. This method also gives sufficient detection of toxic effects on the organisms at very low concentration, which is otherwise not possible in animal testing.

North America held dominant position in the global in vitro toxicity testing market in 2019, accounting for 32.9% share in terms of value, followed by Europe and Asia Pacific, respectively

Questionable predictive power of in vitro toxicity testing is expected to hinder growth of the market. As compared to the conventional animal testing, in vitro toxicity testing has not turned out to be a more reliable predictor. Although in vitro cytotoxicity assays have been used by scientists in drug testing, it has not been consistently applied to the decision making involved in early drug development.

Moreover, the influence of nanomaterial properties on the outcome of in vitro toxicity testing through assay interference is also expected to limit growth of the market. Such interference can lead to false positive or false negative results.

Strict regulations banning animal testing are expected to offer lucrative growth opportunities for players in the global in vitro toxicity market. For instance, in January 2020, the state governments of California, Nevada, and Illinois banned the sale or import of animal-tested cosmetics.

Moreover, increasing demand for personal care products is also expected to aid in growth of the market. For instance, according to India Brand Equity Foundation, the beauty, cosmetic and grooming market in India is expected to reach US$ 20 billion by 2025.

The global in vitro toxicity testing market was valued at US$ 4,745.9 Mn in 2019 and is forecast to reach a value of US$ 14,940.2 Mn by 2027 at a CAGR of 15.4% between 2020 and 2027.


Major regulatory bodies are focused on providing guidelines for in vitro toxicity testing. For instance, in January 2020, the U.S. FDA finalized its In Vitro Guidance for the pharmaceutical industry in order to help drug developers plan and evaluate studies to determine the drug-drug interaction potential of an investigational drug product.

The market is witnessing increasing adoption of Next Generation Sequencing (NGS) as an alternative or supplement to conventional in vivo or in vitro testing methods for biologics testing. For instance, in January 2020, PathoQuest, a strategic partner of Charles River Laboratories International Inc., received its GLP certificate for advanced NGS viral safety testing from the French National Agency for Medicine and Health Products Safety.

Global In Vitro Toxicity Testing Market: Competitive Landscape

Major players operating in the global in vitro toxicity testing market include, Bio-Rad Laboratories, Inc., Cyprotex, Charles River Laboratories International Inc., and Covance Inc.

Global In Vitro Toxicity Testing Market: Key Developments

Major players in the market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in January 2019, LabCorp, along with its subsidiary Covance Inc., partnered with GENFIT, a biopharmaceutical company focused on R&D in liver diseases, for access to non-alcoholic steatohepatitis liver diagnostic test for the clinical research market.

Request A Sample Copy -https://www.coherentmarketinsights.com/insight/request-sample/3855

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
**************************************************************************************